Pyxis Oncology (PYXS) Competitors $0.96 +0.03 (+3.15%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.96 +0.00 (+0.18%) As of 04/17/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYXS vs. SLRN, CADL, SLDB, ACB, PVLA, OLMA, CMPX, IMMP, DRUG, and FHTXShould you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Acelyrin (SLRN), Candel Therapeutics (CADL), Solid Biosciences (SLDB), Aurora Cannabis (ACB), Palvella Therapeutics (PVLA), Olema Pharmaceuticals (OLMA), Compass Therapeutics (CMPX), Immutep (IMMP), Bright Minds Biosciences (DRUG), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry. Pyxis Oncology vs. Acelyrin Candel Therapeutics Solid Biosciences Aurora Cannabis Palvella Therapeutics Olema Pharmaceuticals Compass Therapeutics Immutep Bright Minds Biosciences Foghorn Therapeutics Acelyrin (NASDAQ:SLRN) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, community ranking, institutional ownership, media sentiment, analyst recommendations, valuation and risk. Does the media refer more to SLRN or PYXS? In the previous week, Acelyrin had 2 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Acelyrin and 2 mentions for Pyxis Oncology. Acelyrin's average media sentiment score of 1.07 beat Pyxis Oncology's score of 0.67 indicating that Acelyrin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acelyrin 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in SLRN or PYXS? Pyxis Oncology received 14 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 83.33% of users gave Pyxis Oncology an outperform vote while only 55.17% of users gave Acelyrin an outperform vote. CompanyUnderperformOutperformAcelyrinOutperform Votes1655.17% Underperform Votes1344.83% Pyxis OncologyOutperform Votes3083.33% Underperform Votes616.67% Do insiders & institutionals have more ownership in SLRN or PYXS? 87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by insiders. Comparatively, 9.8% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate SLRN or PYXS? Acelyrin currently has a consensus price target of $9.60, indicating a potential upside of 336.36%. Pyxis Oncology has a consensus price target of $9.20, indicating a potential upside of 855.05%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Acelyrin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acelyrin 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Pyxis Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more risk and volatility, SLRN or PYXS? Acelyrin has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Is SLRN or PYXS more profitable? Pyxis Oncology's return on equity of -36.22% beat Acelyrin's return on equity.Company Net Margins Return on Equity Return on Assets AcelyrinN/A -44.12% -39.02% Pyxis Oncology N/A -36.22%-28.76% Which has preferable valuation and earnings, SLRN or PYXS? Pyxis Oncology has higher revenue and earnings than Acelyrin. Acelyrin is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcelyrinN/AN/A-$381.64M-$2.50-0.88Pyxis Oncology$16.15M3.67-$73.79M-$1.30-0.74 SummaryPyxis Oncology beats Acelyrin on 11 of the 16 factors compared between the two stocks. Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYXS vs. The Competition Export to ExcelMetricPyxis OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.33M$6.44B$5.30B$7.34BDividend YieldN/A3.21%5.45%4.30%P/E Ratio-0.946.8921.8617.80Price / Sales3.67230.51380.6797.70Price / CashN/A65.6738.2634.64Price / Book0.345.936.453.98Net Income-$73.79M$142.99M$3.22B$247.81M1 Month Performance-9.97%-13.57%-9.74%-7.85%1 Year Performance-76.84%-8.90%11.49%1.59% Pyxis Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYXSPyxis Oncology1.2906 of 5 stars$0.96+3.1%$9.20+855.1%-78.7%$59.33M$16.15M-0.9460News CoverageSLRNAcelyrin3.5386 of 5 stars$2.31-4.9%$9.60+315.6%-54.9%$232.64MN/A-0.94135Short Interest ↓Positive NewsCADLCandel Therapeutics2.2803 of 5 stars$4.84+0.4%$21.00+333.9%-16.3%$228.62M$120,000.00-2.8060Short Interest ↑SLDBSolid Biosciences3.4533 of 5 stars$2.94-5.8%$15.67+432.9%-72.5%$227.83M$8.09M-0.97100Positive NewsACBAurora Cannabis0.4202 of 5 stars$4.05+0.7%N/A-32.1%$227.67M$320.81M81.021,340PVLAPalvella Therapeutics3.6128 of 5 stars$20.07-16.3%$43.50+116.7%N/A$221.15M$42.81M-1.66N/AOLMAOlema Pharmaceuticals2.8777 of 5 stars$3.18-2.2%$27.67+770.0%-55.4%$217.30MN/A-1.4570Short Interest ↓Positive NewsCMPXCompass Therapeutics3.2362 of 5 stars$1.57+7.5%$13.38+751.9%+17.4%$217.10M$850,000.00-4.2420Short Interest ↑Gap DownIMMPImmutep1.0929 of 5 stars$1.42-5.3%$8.50+498.6%-30.0%$206.69M$5.14M0.002,021Gap DownDRUGBright Minds Biosciences3.141 of 5 stars$29.25-8.7%$84.33+188.3%+2,705.9%$206.04MN/A-172.05N/ANews CoveragePositive NewsGap DownFHTXFoghorn Therapeutics2.0621 of 5 stars$3.68+7.0%$13.17+257.8%-31.3%$204.65M$22.60M-1.92120Gap Down Related Companies and Tools Related Companies SLRN Alternatives CADL Alternatives SLDB Alternatives ACB Alternatives PVLA Alternatives OLMA Alternatives CMPX Alternatives IMMP Alternatives DRUG Alternatives FHTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYXS) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
